Equities Analysts Offer Predictions for Alkermes Q1 Earnings

Alkermes plc (NASDAQ:ALKS) – Equities researchers at HC Wainwright decreased their Q1 2025 earnings estimates for shares of Alkermes in a research report issued to clients and investors on Thursday, February 13th. HC Wainwright analyst D. Tsao now anticipates that the company will earn $0.22 per share for the quarter, down from their previous forecast of $0.27. HC Wainwright has a “Neutral” rating and a $46.00 price target on the stock. The consensus estimate for Alkermes’ current full-year earnings is $2.23 per share. HC Wainwright also issued estimates for Alkermes’ Q2 2025 earnings at $0.31 EPS and Q4 2025 earnings at $0.39 EPS.

Alkermes (NASDAQ:ALKS) last announced its quarterly earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.11. Alkermes had a net margin of 22.15% and a return on equity of 24.92%.

Several other equities research analysts have also issued reports on ALKS. Cantor Fitzgerald lowered their price target on shares of Alkermes from $48.00 to $43.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. The Goldman Sachs Group upped their target price on shares of Alkermes from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Friday. Stifel Nicolaus raised shares of Alkermes from a “hold” rating to a “buy” rating and upped their target price for the stock from $25.00 to $36.00 in a report on Tuesday, November 5th. StockNews.com raised shares of Alkermes from a “buy” rating to a “strong-buy” rating in a report on Thursday. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of Alkermes in a report on Tuesday, February 11th. They issued a “buy” rating and a $40.00 target price on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $37.25.

Alkermes Trading Down 0.3 %

Shares of Alkermes stock opened at $35.89 on Monday. The firm has a market capitalization of $5.81 billion, a PE ratio of 18.41, a price-to-earnings-growth ratio of 1.83 and a beta of 0.49. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.45 and a quick ratio of 3.03. The company’s fifty day moving average price is $30.40 and its two-hundred day moving average price is $28.81. Alkermes has a 52-week low of $22.90 and a 52-week high of $36.25.

Institutional Trading of Alkermes

A number of hedge funds have recently modified their holdings of the company. CIBC Asset Management Inc raised its position in shares of Alkermes by 4.4% in the 4th quarter. CIBC Asset Management Inc now owns 9,155 shares of the company’s stock valued at $263,000 after acquiring an additional 384 shares during the period. O Shaughnessy Asset Management LLC increased its stake in Alkermes by 3.9% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 14,203 shares of the company’s stock worth $408,000 after purchasing an additional 532 shares in the last quarter. Nicollet Investment Management Inc. increased its stake in Alkermes by 1.7% during the 3rd quarter. Nicollet Investment Management Inc. now owns 43,845 shares of the company’s stock worth $1,227,000 after purchasing an additional 714 shares in the last quarter. KBC Group NV increased its stake in Alkermes by 18.8% during the 3rd quarter. KBC Group NV now owns 4,890 shares of the company’s stock worth $137,000 after purchasing an additional 774 shares in the last quarter. Finally, Sei Investments Co. increased its stake in Alkermes by 1.1% during the 4th quarter. Sei Investments Co. now owns 75,394 shares of the company’s stock worth $2,168,000 after purchasing an additional 828 shares in the last quarter. 95.21% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Craig C. Hopkinson sold 9,221 shares of the stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $31.50, for a total value of $290,461.50. Following the sale, the executive vice president now directly owns 59,730 shares in the company, valued at $1,881,495. This trade represents a 13.37 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Christian Todd Nichols sold 5,208 shares of the stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $29.15, for a total transaction of $151,813.20. Following the completion of the sale, the senior vice president now owns 60,703 shares in the company, valued at $1,769,492.45. This represents a 7.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 323,608 shares of company stock worth $10,854,725 in the last 90 days. Corporate insiders own 4.89% of the company’s stock.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.